Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue (2018 - 2026)

Arcturus Therapeutics Holdings' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 39.94% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 39.94% YoY) and the FY2025 annual result came in at $8.2 million, down 57.74% from the prior year.
• Current Deferred Revenue was $7.6 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $8.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $71.5 million in Q1 2024 and bottomed at $4.7 million in Q3 2022.
• A 5-year average of $28.9 million and a median of $26.9 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue sank 91.92% — and 2023, when it soared 775.6%.
• Arcturus Therapeutics Holdings' Current Deferred Revenue stood at $28.6 million in 2022, then surged by 56.48% to $44.8 million in 2023, then slumped by 56.47% to $19.5 million in 2024, then tumbled by 57.74% to $8.2 million in 2025, then decreased by 7.71% to $7.6 million in 2026.
• Business Quant data shows ARCT's Current Deferred Revenue at $7.6 million in Q1 2026, $8.2 million in Q4 2025, and $6.8 million in Q3 2025.